Generate Biomedicines · 公司档案

公开已核验进展

当前没有符合条件的公开已核验事件。

合作、许可与并购时间线

当前显示的公开进展中没有合作、许可或并购节点；这不代表该公司从未发生相关活动。

以上来自最新 0 条已核验进展。合作事件成立与模型效果、实验结果或临床进度分别需要证据。

公开原文线索

• Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer

  Generate Biomedicines official news-release RSS · 行业原文收录 · 来源发布：Thu Oct 01 2026 11:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)

  Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical trial underway at Roswel

  原始出处

• Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

  Generate Biomedicines official news-release RSS · 行业原文收录 · 来源发布：Thu Feb 26 2026 23:11:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)

  SOMERVILLE, Mass., February 26, 2026 — Generate Biomedicines, Inc. (Nasdaq: GENB) (“Generate”), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development, t

  原始出处

• Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI

  Generate Biomedicines official news-release RSS · 行业原文收录 · 来源发布：Mon Dec 01 2025 10:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)

  SOLAIRIA‑1 and SOLAIRIA‑2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 studies of a long-a

  原始出处

• Generate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma at the European Respiratory Society International Congress

  Generate Biomedicines official news-release RSS · 行业原文收录 · 来源发布：Thu Sep 25 2025 11:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)

  GB-0895, a next-generation, ultra-high affinity anti-TSLP monoclonal antibody, demonstrated prolonged half-life and sustained pharmacology in asthma patients GB-0895 is optimized for a single subcutaneous injection every

  原始出处

已验证的官方与订阅来源

• Generate Biomedicines official news-release RSS · 采集已启用 · 最近成功 Thu Oct 08 2026 15:07:25 GMT+0000 (Coordinated Universal Time)

来源验证与持续采集分别显示；原文收录不自动成为已核验事件。